Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jacob Gottlieb, Visium Asset Management Boost Exposure to QLT Inc.

Jacob Gottlieb‘s hedge fund, Visium Asset Management, has boosted its position in biotechnology company QLT Inc. (USA) (NASDAQ:QLTI), a new filing with the SEC revealed. Visium currently holds 3.5 million shares of the company, equal to 6.8% of the common stock, and up from 2.0 million revealed in its latest 13F.  The stake is passive by nature, and, at the current share price of QLT, the position’s value amounts to $17.9 million.


The stock of QLT has been down by over 30% since the beginning of the year. For the third quarter of the year, the company posted a loss from continuing operations of $0.15 per share, versus $0.25 in the same period of last year. At the same time, the company reported an almost flat Research & Development expense of $5.2 million. QLT is engaged in production and marketing of ocular products. Also, earlier this year, the company conducted a cash distribution worth $200 million.

Several hedge funds out of those we track have been keeping their long positions in QLT. As follows, Axial Capital, led by Eliav Assouline and Marc Andersen holds 8.9 million shares of the company, worth $41.1 million. Julian Baker And Felix Baker’s Baker Bros. Advisors, and Kevin Kotler’s Broadfin Capital disclosed ownership of 1.5 million shares, and 784,900 shares respectively, with values of $7.1 million, and $3.6 million respectively. All three holdings have remained flat over the quarter.

Jacob Gottlieb and Visium Asset Management caught our attention earlier in October, when they revealed initiating a position in MEI Pharma Inc (NASDAQ:MEIP). The stake amasses over 5% of the company and contains some 932,000 shares.

In the latest 13F, Visium disclosed its largest position in Allergan, Inc. (NYSE:AGN), in which it holds 2.8 million shares, worth $251.6 million. In Cardinal Health, Inc. (NYSE:CAH), the fund holds a $236.2 million stake, which amasses 4.5 million shares. The third-largest is Perrigo Company (NASDAQ:PRGO), in which Visium disclosed ownership of 1.6 million shares, worth $203.3 million.

Disclosure: none

Recommended Reading:

Leon Cooperman Discloses Initial Stake in Atlas Resource Partners

Quadrangle Gp Investors Limits Exposure to Lumos Networks

Oaktree Capital Management Slightly Reduces Position in LSE-listed Stock Spirits Group

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!